We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
Read MoreHide Full Article
Shares of Cassava Sciences (SAVA - Free Report) plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, simufilam, failed to meet the prespecified co-primary endpoints in the second late-stage study for Alzheimer’s disease (AD). Simufilam is SAVA’s proprietary, investigational oral small molecule that targets the filamin A protein.
Cassava released top-line results from the phase III REFOCUS-ALZ study, which evaluated simufilam in patients with mild-to-moderate AD. Treatment with the drug failed to achieve a significant reduction in cognitive and functional decline in AD patients when compared to placebo over 76 weeks, as assessed by the ADAS-COG12 and ADCS-ADL scales. The study also failed to meet any pre-specified secondary and exploratory biomarker endpoints.
The REFOCUS-ALZ study had enrolled 1,125 AD patients who were randomized equally to receive either a twice-daily, oral dose of simufilam (50 mg or 100 mg tablets) or placebo for 76 weeks. The candidate, however, demonstrated an acceptable safety profile in the study.
Year to date, Cassava shares have plunged 19.5% against the industry’s 0.5% growth.
Image Source: Zacks Investment Research
SAVA’s AD Drug Failure in First Late-Stage Study
Under its AD program, Cassava evaluated simufilam in another late-stage study. In November 2024, the company faced a massive setback after it reported that the candidate failed to meet the primary endpoints in the late-stage RETHINK-ALZ study, which evaluated simufilam in patients with mild-to-moderate AD. Treatment with the drug failed to achieve a significant reduction in cognitive or functional decline in AD patients when compared to placebo over 52 weeks, as assessed by the ADAS-COG12 and ADCS-ADL scales. The study failed to meet any pre-specified secondary and exploratory biomarker endpoints as well.
Based on the above study results, SAVA had discontinued the 76-week phase III REFOCUS-ALZ study and the open-label extension study on the drug.
SAVA’s Next Steps
Following simufilam’s failure to demonstrate therapeutic benefit in AD patients in two late-stage studies, Cassava expects to phase out the AD program by the end of the second quarter of 2025. Despite the setbacks, SAVA has reportedly initiated preclinical studies to evaluate simufilam’s potential as a treatment for tuberous sclerosis complex-related epilepsy.
In early January, Cassava announced plans to reduce its workforce by 33% in first-quarter 2025 as part of ongoing cost management efforts. Additionally, it will discontinue the planned biomarker analysis of plasma samples from past mid-stage studies. The workforce reduction is expected to result in a one-time cost of approximately $0.4 million in first-quarter 2025.
Cassava ended the fourth quarter of 2024 with a cash balance of approximately $128.6 million.
Currently, there are two drugs approved by the FDA in the AD space — Leqembi and Kisunla. Both these drugs are approved to treat early symptomatic AD, which includes mild cognitive impairment or dementia stage of the disease.
Eli Lilly and Biogen/Eisai drugs are based on similar mechanisms, reducing the accumulation of amyloid beta (Aβ) plaque in the brain. Aβ is a protein that is said to be the primary cause of the cognitive decline associated with AD.
In the past 30 days, Gilead Sciences’ earnings estimate for 2025 has improved from $7.81 to $7.87 per share. During the same timeframe, the estimate for earnings per share for 2026 has improved from $8.11 to $8.27. Year to date, shares of Gilead Sciences have gained 16.8%.
GILD’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.47%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
Shares of Cassava Sciences (SAVA - Free Report) plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, simufilam, failed to meet the prespecified co-primary endpoints in the second late-stage study for Alzheimer’s disease (AD). Simufilam is SAVA’s proprietary, investigational oral small molecule that targets the filamin A protein.
Cassava released top-line results from the phase III REFOCUS-ALZ study, which evaluated simufilam in patients with mild-to-moderate AD. Treatment with the drug failed to achieve a significant reduction in cognitive and functional decline in AD patients when compared to placebo over 76 weeks, as assessed by the ADAS-COG12 and ADCS-ADL scales. The study also failed to meet any pre-specified secondary and exploratory biomarker endpoints.
The REFOCUS-ALZ study had enrolled 1,125 AD patients who were randomized equally to receive either a twice-daily, oral dose of simufilam (50 mg or 100 mg tablets) or placebo for 76 weeks. The candidate, however, demonstrated an acceptable safety profile in the study.
Year to date, Cassava shares have plunged 19.5% against the industry’s 0.5% growth.
Image Source: Zacks Investment Research
SAVA’s AD Drug Failure in First Late-Stage Study
Under its AD program, Cassava evaluated simufilam in another late-stage study. In November 2024, the company faced a massive setback after it reported that the candidate failed to meet the primary endpoints in the late-stage RETHINK-ALZ study, which evaluated simufilam in patients with mild-to-moderate AD. Treatment with the drug failed to achieve a significant reduction in cognitive or functional decline in AD patients when compared to placebo over 52 weeks, as assessed by the ADAS-COG12 and ADCS-ADL scales. The study failed to meet any pre-specified secondary and exploratory biomarker endpoints as well.
Based on the above study results, SAVA had discontinued the 76-week phase III REFOCUS-ALZ study and the open-label extension study on the drug.
SAVA’s Next Steps
Following simufilam’s failure to demonstrate therapeutic benefit in AD patients in two late-stage studies, Cassava expects to phase out the AD program by the end of the second quarter of 2025. Despite the setbacks, SAVA has reportedly initiated preclinical studies to evaluate simufilam’s potential as a treatment for tuberous sclerosis complex-related epilepsy.
In early January, Cassava announced plans to reduce its workforce by 33% in first-quarter 2025 as part of ongoing cost management efforts. Additionally, it will discontinue the planned biomarker analysis of plasma samples from past mid-stage studies. The workforce reduction is expected to result in a one-time cost of approximately $0.4 million in first-quarter 2025.
Cassava ended the fourth quarter of 2024 with a cash balance of approximately $128.6 million.
Cassava Sciences, Inc. Price and Consensus
Cassava Sciences, Inc. price-consensus-chart | Cassava Sciences, Inc. Quote
Marketed Drugs in the AD Space
Currently, there are two drugs approved by the FDA in the AD space — Leqembi and Kisunla. Both these drugs are approved to treat early symptomatic AD, which includes mild cognitive impairment or dementia stage of the disease.
Leqembi, which was approved in 2023, is marketed by Japan-based Eisai in partnership with the Biogen (BIIB - Free Report) market. Kisunla was developed by Eli Lilly (LLY - Free Report) and received the FDA’s approval in 2024.
Eli Lilly and Biogen/Eisai drugs are based on similar mechanisms, reducing the accumulation of amyloid beta (Aβ) plaque in the brain. Aβ is a protein that is said to be the primary cause of the cognitive decline associated with AD.
SAVA’s Zacks Rank and Another Stock to Consider
Cassava currently carries a Zacks Rank #2 (Buy).
Another top-ranked stock from the sector is Gilead Sciences (GILD - Free Report) , carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, Gilead Sciences’ earnings estimate for 2025 has improved from $7.81 to $7.87 per share. During the same timeframe, the estimate for earnings per share for 2026 has improved from $8.11 to $8.27. Year to date, shares of Gilead Sciences have gained 16.8%.
GILD’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.47%.